Cell & Gene Therapy
Expertise: Cell & Gene Therapy 62 results
Cell & Gene Therapy
Decision-Ready Data: A Playbook for Cell and Gene Therapy Sponsors
Advancing Efficient, Sustainable Execution Across the CGT Lifecycle Cell and gene therapy (CGT) programs offer tremendous scientific promise, but operational complexity can quickly consume valuable time and capital. High per-patient costs, manufacturing dependencies, lengthy site activation, complex logistics, and long-term...
Cell & Gene Therapy
11th Annual CAR-TCR Summit
Cell & Gene Therapy
Patient-Centered Execution Across Cell, Gene, and RNA Therapeutics
Cell, Gene, and RNA Therapies are shifting the aim of drug development from managing symptoms to delivering durable, potentially curative therapies. But moving a construct from a promising preclinical milestone to a viable commercial asset—whether an ex vivo cell therapy, an in vivo viral vector, or an RNA...
Cell & Gene Therapy
When Logistics Become a Strategic Advantage in CGT Trials
Chain of custody, manufacturing coordination, and site workflows that keep cell and gene therapy studies moving In cell and gene therapy trials, logistics are more than an operational consideration. A missed collection, delayed shipment, manufacturing issue, or temperature excursion can...
Cell & Gene Therapy
Accelerating Time to Data in Cell and Gene Therapy Trials
Cell & Gene Therapy
Accelerating Time to Data in Cell and Gene Therapy Trials
Cell & Gene Therapy
Leslie Amos
The Cell and Gene Therapy (CGT) sector continues to progress toward a demonstrably execution-centric development paradigm, in which asset valuation is increasingly influenced by the capacity to integrate scientific innovation with operational precision, manufacturing robustness, and evidence strategies that withstand...
Cell & Gene Therapy
Scaling CGT Trials: The Critical Role of Emerging Research Centers
The cell and gene therapy (CGT) landscape has entered a period of unprecedented growth. Dozens of CGT products have already been approved globally, and more than 4,300 therapies—from AAV gene therapies to RNA-based and gene-modified cell therapies—are moving through development.i...